Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease

Archives of Dermatology

Volumn 144, Issue 9, 2008, Pages 1106-1109

  Moreno Romero, Juan A ^a,c   Fernández Avilés, Francesc ^b   Carreras, Enric ^b   Rovira, Montserrat ^b   Martínez, Carmen ^b   Mascaró Jr , José M ^a,c  

^a Department of Dermatology ^*  (Spain)

^b Department Hematology   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CLOFAZIMINE; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; IMATINIB; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN; RETINOID; RITUXIMAB; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DRUG WITHDRAWAL; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; LICHEN SCLEROSUS ET ATROPHICUS; LOW DRUG DOSE; MALE; MONITORING; PHILADELPHIA CHROMOSOME POSITIVE CELL; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PUVA; SCLERODERMA; SCLERODERMATOUS CHRONIC GRAFT VERSUS HOST DISEASE; SKIN BIOPSY;

ADOLESCENT; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SCLERODERMA, LOCALIZED;

EID: 52149086740     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.9.1106     Document Type: Article

References (11)

1. Lee JH, Lee JH, Choi SJ, et al. Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation. Br J Haematol. 2003;122(4):637-644.
2. Chosidow O, Bagot M, Vernant JP, et al. Sclerodermatous chronic graft-versus-host disease: analysis of seven cases. J Am Acad Dermatol. 1992;26(1):49-55.
3. White JM, Creamer D, du Vivier AW, et al. Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges. Br J Dermatol. 2007; 156(5)1032-1038.
4. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354(25):2667-2676.
5. Gabrielli A, Svegliati S, Moroncini G, Luchetti M, Tonnini C, Avvedimento EV. Stimulatory antibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmun Rev. 2007;7(2):121-126.
6. Svegliati S. Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor In patients with extensive chronic graft-versus-host disease. Blood. 2007; 110(1):237-241.
7. Mapara MY. Stimulating results with stimulatory antibodies. Blood. 2007;110(1): 6-7.
8. Seggewiss R. Loré K, Greiner E, etal. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation In a dose-dependent manner. Blood. 2005; 105(6):2473-2479.
9. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with Imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23 (4):866-873.
10. Distler JH, Jüngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56(1):311-322.
11. Lozano E. Segarra M. Cid MC. Stimulatory autoantibodies to the PDGF receptor In scleroderma. N Engl J Med. 2006;355(12):1278-1279.